Results 161 to 170 of about 6,421 (186)

Methylprednisolone/nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +1 more source

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
Kiat Ruxrungtham
exaly  

Carfilzomib/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Dobutamine/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Lancet, The, 2006
Sharon L Walmsley, Bonaventura Clotet, Adriano Lazzarin   +2 more
exaly  

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Lancet, The, 2007
Bonaventura Clotet, Jean-Christophe Goffard, Adriano Lazzarin   +2 more
exaly  

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

New England Journal of Medicine, 2002
Sharon L Walmsley
exaly  

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Lancet, The, 2015
Tarik Asselah, K Rajender Reddy, Marina Berenguer   +2 more
exaly  

Wer bekommt Nirmatrelvir/Ritonavir?

Im Fokus Onkologie, 2023
openaire   +1 more source

Nirmatrelvir+ritonavir/paracetamol/tacrolimus

Reactions Weekly, 2023
openaire   +1 more source